67 related articles for article (PubMed ID: 19914831)
1. p16(INK4a) Peptide mimetics identified via virtual screening.
Klein MA; Mayo KH; Kratzke RA
Bioorg Med Chem Lett; 2010 Jan; 20(1):403-5. PubMed ID: 19914831
[TBL] [Abstract][Full Text] [Related]
2. Reducing CDK4/6-p16(INK4a) interface. Computational alanine scanning of a peptide bound to CDK6 protein.
Villacañas O; Rubio-Martinez J
Proteins; 2006 Jun; 63(4):797-810. PubMed ID: 16508961
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
Villacañas O; Pérez JJ; Rubio-Martínez J
J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
[TBL] [Abstract][Full Text] [Related]
4. C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells.
Fahham N; Sardari S; Ostad SN; Vaziri B; Ghahremani MH
J Cell Biochem; 2010 Dec; 111(6):1598-606. PubMed ID: 21053367
[TBL] [Abstract][Full Text] [Related]
5. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
6. Protein folding and stability of human CDK inhibitor p19(INK4d).
Zeeb M; Rösner H; Zeslawski W; Canet D; Holak TA; Balbach J
J Mol Biol; 2002 Jan; 315(3):447-57. PubMed ID: 11786024
[TBL] [Abstract][Full Text] [Related]
7. RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors.
Zhang S; Tang Q; Xu F; Xue Y; Zhen Z; Deng Y; Liu M; Chen J; Liu S; Qiu M; Liao Z; Li Z; Luo D; Shi F; Zheng Y; Bi F
Mol Cancer Res; 2009 Apr; 7(4):570-80. PubMed ID: 19372585
[TBL] [Abstract][Full Text] [Related]
8. The physiology of p16(INK4A)-mediated G1 proliferative arrest.
Shapiro GI; Edwards CD; Rollins BJ
Cell Biochem Biophys; 2000; 33(2):189-97. PubMed ID: 11325039
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of p16ink4a-binding proteins.
Souza-Rodrígues E; Estanyol JM; Friedrich-Heineken E; Olmedo E; Vera J; Canela N; Brun S; Agell N; Hübscher U; Bachs O; Jaumot M
Proteomics; 2007 Nov; 7(22):4102-11. PubMed ID: 17955473
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.
Fåhraeus R; Paramio JM; Ball KL; Laín S; Lane DP
Curr Biol; 1996 Jan; 6(1):84-91. PubMed ID: 8805225
[TBL] [Abstract][Full Text] [Related]
11. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts.
Fåhraeus R; Lane DP
EMBO J; 1999 Apr; 18(8):2106-18. PubMed ID: 10205165
[TBL] [Abstract][Full Text] [Related]
12. Cloning and characterization of murine p16INK4a and p15INK4b genes.
Quelle DE; Ashmun RA; Hannon GJ; Rehberger PA; Trono D; Richter KH; Walker C; Beach D; Sherr CJ; Serrano M
Oncogene; 1995 Aug; 11(4):635-45. PubMed ID: 7651726
[TBL] [Abstract][Full Text] [Related]
13. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
[TBL] [Abstract][Full Text] [Related]
14. P300 plays a role in p16(INK4a) expression and cell cycle arrest.
Wang X; Pan L; Feng Y; Wang Y; Han Q; Han L; Han S; Guo J; Huang B; Lu J
Oncogene; 2008 Mar; 27(13):1894-904. PubMed ID: 17906698
[TBL] [Abstract][Full Text] [Related]
15. The Pezcoller lecture: cancer cell cycles revisited.
Sherr CJ
Cancer Res; 2000 Jul; 60(14):3689-95. PubMed ID: 10919634
[TBL] [Abstract][Full Text] [Related]
16. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
[TBL] [Abstract][Full Text] [Related]
17. Co-transfection of p16(INK4a) and p53 genes into the K562 cell line inhibits cell proliferation.
Rui HB; Su JZ
Haematologica; 2002 Feb; 87(2):136-42. PubMed ID: 11836163
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
[TBL] [Abstract][Full Text] [Related]
19. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
